Dose-dense Weekly Paclitaxel Does Not Increase PFS

(March 3, 2016) In a study published in the New England Journal of Medicine this week, researchers report that a dose-dense weekly paclitaxel regimen failed to improve progression-free survival in advanced ovarian cancer versus a conventional regimen and optional bevacizumab (Avastin). Patients treated with weekly paclitaxel plus carboplatin had a median PFS of 14.7 months compared […]